Geron Corporation has entered into a first amendment to its existing loan agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, investment funds managed by Pharmakon Advisors, LP, with BioPharma Credit PLC serving as collateral agent. The amended agreement maintains a five-year senior secured term loan facility of up to $250 million, divided into three tranches: a $125 million Tranche A loan funded in November 2024, a $75 million Tranche B loan available at Geron's option, and a $50 million Tranche C loan contingent on achieving a specified RYTELO™ revenue milestone. The amendment extends the deadline for requesting Tranche B and C loans from December 31, 2025, to July 30, 2026, and pushes the makewhole date from November 1, 2026, to May 1, 2027. All other terms of the loan agreement remain unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-003388), on January 06, 2026, and is solely responsible for the information contained therein.